Efficacy and Safety Study of Rimegepant for the Preventative Treatment of Migraine in Pediatric Subjects

The purpose of this study is to compare the efficacy and safety of rimegepant to placebo as a preventative treatment for migraine in children and adolescents ≥ 6 to 18 years with episodic migraine.

Study ID: 3434
NCT Number: NCT05156398
Principal Investigator: Zhao Liu, MD
Department: Pediatrics-Neurology
Eligibility: Both men and women 6 years old to 17 years old. Does not accept healthy volunteers.

For questions about this study, please contact:

ClinicalTrialsInterest@health.missouri.edu
(573) 882-7026